Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
-
Published:2021-04
Issue:
Volume:147
Page:128-139
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Heinrich KathrinORCID, Modest Dominik P., Ricard IngridORCID, Fischer von Weikersthal LudwigORCID, Decker Thomas, Kaiser Florian, Graeven Ullrich, Uhlig Jens, Schenk MichaelORCID, Freiberg-Richter Jens, Peuser Bettina, Denzlinger Claudio, Giessen-Jung Clemens, Stahler ArndtORCID, Michl Marlies, Held Swantje, Jung Andreas, Kirchner Thomas, Stintzing SebastianORCID, Heinemann Volker
Subject
Cancer Research,Oncology
Reference43 articles.
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Canc,2015 2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Canc,2013 3. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial 4. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial;Ducreux;Lancet Oncol,2011 5. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial;Cunningham;Lancet Oncol,2013
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|